The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Salazar, Nicole ^a   Muñoz, Daniel ^b   Kallifatidis, Georgios ^a   Singh, Rajendra K ^a   Jordà, Mercè ^a   Lokeshwar, Bal L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Research Service and GRECC   (United States)

Author keywords

Breast cancer cell proliferation; Chemokine receptor; CXCR7; EGFR; Heterodimerization; arrestin2

Indexed keywords

CHEMOKINE RECEPTOR CXCR7; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LIPOCORTIN 5; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; BETA ARRESTIN; CHEMOKINE RECEPTOR CXCR; CXCR7 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; RETINA S ANTIGEN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; BREAST TUMOR; FEMALE; GENE SILENCING; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ARRESTINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAMMARY GLANDS, HUMAN; MCF-7 CELLS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CXCR; SIGNAL TRANSDUCTION;

EID: 84907046942     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-198     Document Type: Article

References (47)

1. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203(9):2201-2213. 10.1084/jem.20052144, 2118398, 16940167.
2. Tarnowski M, Grymula K, Liu R, Tarnowska J, Drukala J, Ratajczak J, Mitchell RA, Ratajczak MZ, Kucia M. Macrophage Migration Inhibitory Factor Is Secreted by Rhabdomyosarcoma Cells, Modulates Tumor Metastasis by Binding to CXCR4 and CXCR7 Receptors and Inhibits Recruitment of Cancer-Associated Fibroblasts. Mol Cancer Res 2010, 8(10):1328-1343. 10.1158/1541-7786.MCR-10-0288, 2974061, 20861157.
3. Balabanian K, Lagane B, Infantino S, Chow KYC, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005, 280(42):35760-35766. 10.1074/jbc.M508234200, 16107333.
4. Lagane B, Chow KYC, Balabanian K, Levoye A, Harriague J, Planchenault T, Baleux F, Gunera-Saad N, Arenzana-Seisdedos F, Bachelerie F. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 2008, 112(1):34-44. 10.1182/blood-2007-07-102103, 18436740.
5. Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S, Wilson D, Xu QL, Raz E. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008, 132(3):463-473. 10.1016/j.cell.2007.12.034, 18267076.
6. Allen SJ, Crown SE, Handel TM. Chemokine: Receptor structure, interactions, and antagonism. Annu Rev Immunol 2007, 25:787-820. 10.1146/annurev.immunol.24.021605.090529, 17291188.
7. Grodecka M, Wasniowska K. Interceptors:-"silent" chemokine receptors. Postepy Hig Med Dosw (Online) 2007, 61:231-239.
8. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A 2010, 107(2):628-632. 10.1073/pnas.0912852107, 2818968, 20018651.
9. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A 2001, 98(5):2449-2454. 10.1073/pnas.041604898, 30158, 11226259.
10. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007, 117(9):2445-2458. 10.1172/JCI31901, 1952636, 17786238.
11. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, Lefkowitz RJ, Luttrell LM. The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 2000, 275(13):9572-9580. 10.1074/jbc.275.13.9572, 10734107.
12. Torossian F, Anginot A, Chabanon A, Clay D, Guerton B, Desterke C, Boutin L, Marullo S, Scott MG, Lataillade JJ, Le Bousse-Kerdile`s MC. CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation. Blood 2014, 123(2):191-202. 10.1182/blood-2013-05-500496, 24277075.
13. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007, 104:15735-15740. 10.1073/pnas.0610444104, 1994579, 17898181.
14. Wang JH, Shiozawa YS, Wang JC, Wang Y, Jung YH, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008, 283(7):4283-4294. 10.1074/jbc.M707465200, 18057003.
15. Singh RK, Lokeshwar BL. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 2011, 71(9):3268-3277. 10.1158/0008-5472.CAN-10-2769, 3085571, 21398406.
16. Van Rechem C, Rood BR, Touka M, Pinte S, Jenal M, Gue´rardel C, Ramsey K, Monte´ D, Be´gue A, Tschan MP, Stephan DA, Leprince D. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem 2009, 284(31):20927-20935. 10.1074/jbc.M109.022350, 2742858, 19525223.
17. Liu H, Xue W, Ge G, Luo X, Li Y, Xiang H, Ding X, Tian P, Tian X. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1 alpha in MSCs. Biochem Biophys Res Commun 2010, 401(4):509-515. 10.1016/j.bbrc.2010.09.076, 20869949.
18. Tarnowski M, Grymula K, Reca R, Jankowski K, Maksym R, Tarnowska J, Przybylski G, Barr FG, Kucia M, Ratajczak MZ. Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res 2010, 8(1):1-14. 10.1158/1541-7786.MCR-09-0259, 2943743, 20068066.
19. Tarnowski M, Liu R, Wysoczynski M, Ratajczak J, Kucia M, Ratajczak MZ. CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur J Haematol 2010, 85(6):472-483. 10.1111/j.1600-0609.2010.01531.x, 20887389.
20. Maksym RB, Tarnowski M, Grymula K, Tarnowska J, Wysoczynski M, Liu R, Czerny B, Ratajczak J, Kucia M, Ratajczak MZ. The role of stromal-derived factor-1-CXCR7 axis in development and cancer. Eur J Pharmacol 2009, 625(1-3):31-40. 2783873, 19835865.
21. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
22. Boudot A, Kerdivel G, Habauzit D, Eeckhoute J, Dily L, Samson M, Pakdel F. Differential Estrogen-Regulation of CXCL12 Chemokine Receptors, CXCR4 and CXCR7, Contributes to the Growth Effect of Estrogens in Breast Cancer Cells. PLoS One 2011, 6(6):1-12.
23. Ma X-J, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009, 11(1):R7. 10.1186/bcr2222, 2687710, 19187537.
24. Wang Y, Li G, Stanco A, Long JE, Crawford D, Potter GB, Pleasure SJ, Behrens T, Rubenstein JLR. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 2011, 69(1):61-76. 10.1016/j.neuron.2010.12.005, 3025760, 21220099.
25. Lee E, Han J, Kim K, Choi H, Cho E-G, Lee TR. CXCR7 mediates SDF1-induced melanocyte migration. Pigment Cell Melanoma Res 2013, 26(1):58-66. 10.1111/pcmr.12024, 22978759.
26. Puchert M, Engele J. The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets. Cell Tissue Res 2014, 355(2):239-253. 10.1007/s00441-013-1747-y, 24292718.
27. Clark GM, Sledge GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987, 5(1):55-61.
28. Luker KE, Sa L, La M, Schmidt BT, Winkler JS, Coggins NL, Thomas DG, Luker GD. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2011, 2012:1-9.
29. Nigam N, Prasad S, George J, Shukla Y. Lupeol induces p53 and cyclin-B-mediated G2/M arrest and targets apoptosis through activation of caspase in mouse skin. Biochem Biophys Res Commun 2009, 381(2):253-258. 10.1016/j.bbrc.2009.02.033, 19232320.
30. Luker KE, Gupta M, Luker GD. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7. Biotechniques 2009, 47(1):625-632. 10.2144/000113126, 19594447.
31. Luker KE, Steele JM, Mihalko L, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 2010, 29(32):4599-4610. 10.1038/onc.2010.212, 3164491, 20531309.
32. Hernandez L, Magalhaes MO, Coniglio SJ, Condeelis JS, Segall JE. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 2011, 13(6):R128-R128. 10.1186/bcr3074, 3326570, 22152016.
33. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005, 7(4):R402-R410. 10.1186/bcr1022, 1175055, 15987445.
34. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004, 14(3):171-179. 10.1016/j.semcancer.2003.10.003, 15246052.
35. Mu¨ller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Vera´stegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56. 10.1038/35065016, 11242036.
36. Schrevel M, Karim R, ter Haar NT, van der Burg SH, Trimbos JBMZ, Fleuren GJ, Gorter A, Jordanova ES. CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br J Cancer 2012, 106(9):1520-1525. 10.1038/bjc.2012.110, 3341866, 22531719.
37. Yates TJ, Knapp J, Gosalbez M, Lokeshwar SD, Gomez CS, Benitez A, Ekwenna OO, Young EE, Manoharan M, Lokeshwar VB. C-X-C chemokine receptor 7: A functionally associated molecular marker for bladder cancer. Cancer 2013, 119(1):61-71. 10.1002/cncr.27661, 3461116, 22736438.
38. Sa´nchez-Marti´n L, Sa´nchez-Mateos P, Cabañas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 2013, 19(1):12-22. 10.1016/j.molmed.2012.10.004, 23153575.
39. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113(24):6085-6093. 10.1182/blood-2008-12-196618, 19380869.
40. Berahovich RD, Zabel BA, Lewen S, Walters MJ, Ebsworth K, Wang Y, Jaen JC, Schall TJ. Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Immunology 2014, 141(1):111-122. 10.1111/imm.12176, 24116850.
41. Chinni SR, Yamarnoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008, 6(3):446-457. 10.1158/1541-7786.MCR-07-0117, 3842603, 18337451.
42. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G. beta-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 2003, 100(20):11406-11411. 10.1073/pnas.1936664100, 208770, 13679574.
43. Michal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, Benovic JL. Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Res Treat 2011, 130(3):791-807. 10.1007/s10549-011-1374-9, 3156829, 21318602.
44. Salazar N, Munoz D, Hoy J, Lokeshwar BL. Use of shRNA for Stable Suppression of Chemokine Receptor Expression and Function in Human Cancer Cell Lines. Methods Mole Biol 2014, 1172:209-218.
45. Luker KE, Gupta M, Steele JM, Foerster BR, Luker GD. Imaging Ligand-Dependent Activation of CXCR7. Neoplasia 2009, 11(10):1022-1035. 2745668, 19794961.
46. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002, 98(2):297-309. 10.1002/ijc.10168, 11857423.
47. Rhodes DR, Yu JJ, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6(1):1-6. 10.1016/S1476-5586(04)80047-2, 1635162, 15068665.